Core Viewpoint - Huajian Medical (01931) has seen a stock increase of over 11%, currently at 1.78 HKD, with a trading volume of 20.59 million HKD, following the announcement of a dual-platform testing solution for Nipah virus developed by its subsidiary, Shenzhen Carbon Hua Biotechnology Co., Ltd [1] Group 1 - The dual-platform testing solution includes a smart fluorescence PCR rapid detection platform and a high-throughput sequencing and intelligent analysis platform, providing comprehensive technical support from rapid screening to precise tracing [1] - The rapid implementation of Nipah virus testing capabilities showcases the technological strength of Carbon Hua Biotechnology and represents a significant step in Huajian Medical's overall AI healthcare strategy [1] - The company is accelerating the establishment of a next-generation public health prevention and control paradigm, integrating "AI early warning + rapid diagnosis + ecological collaboration," as it progresses with the acquisition of Chuangye Huikang Technology Co., Ltd (300451.SZ) [1]

Group 1 - The Hang Seng Index rose by 1.07%, gaining 287 points, while the Hang Seng Tech Index increased by 0.20%. The early trading volume in Hong Kong stocks reached HKD 134.8 billion [1] - Zijin Mining (02899) surged over 4% as it plans to acquire African gold mines for HKD 28 billion, while Zijin Gold International (02259) rose by 10.63% [1] - Anta Sports (02020) increased by 1.38% after announcing a plan to acquire a 29.06% stake in Puma for EUR 1.5 billion [1] - Zhaoyi Innovation (03986) saw a rise of over 5%, with all storage products experiencing price increases, and the company expects a 46% year-on-year growth in net profit for the year [1] - GDS Holdings (09698) rose over 6% due to high demand for AI computing power driving data center growth [1] - Bilibili (09626) increased by nearly 5%, with AI applications becoming the core driver of advertising revenue growth for the platform [1] - Conant Optical (02276) surged over 4% to reach a new high, planning a discounted share placement to raise nearly HKD 1.4 billion for XR-related production lines and R&D [1] - ASMPT (00522) rose over 5% as the company plans to divest its SMT business, which Citigroup believes will help unlock company value [1] - Harbin Electric (01133) jumped 7% after a profit warning, expecting net profit attributable to shareholders to reach approximately HKD 2.65 billion by 2025 [1] - Aidi Kang Holdings (09860) surged over 27% following a report from Jefferies highlighting the company's strategic positioning in AI medical diagnostics and its significant acquisition of Crown Bioscience [1] Group 2 - Wangshan Wangshui-B (02630) briefly rose over 11% to a new high, with research indicating that VV116 has potential therapeutic effects against Nipah virus [2] Group 3 - Yijun Group Holdings (02442) experienced a high-level retreat of over 39%, with its stock price having previously surged 4.4 times within two months of resuming trading [3] - Junda Co., Ltd. (02865) fell over 11%, as the company stated that its recent ventures are still in the technical exploration phase [3]

Core Viewpoint - Adicon Holdings (09860) has seen a significant stock price increase, rising over 37% in early trading and currently up 21.85% to HKD 6.58, with a trading volume of HKD 68.54 million [1] Group 1: Acquisition Details - In November of last year, Adicon announced the acquisition of 100% equity in Crown Bioscience for USD 204 million, expected to be completed by mid-2026 [1] - Crown Bioscience specializes in translational oncology and immuno-oncology, possessing the largest commercial PDX model library globally and serving over 1,100 clients, including the top 20 pharmaceutical companies [1] Group 2: Strategic Implications - According to the latest report from Jefferies, Adicon's strategic positioning in AI medical testing and the acquisition of Crown Bioscience will significantly enhance its comprehensive strength in the drug development and diagnostic value chain [1] - The acquisition is expected to substantially improve Adicon's capabilities in preclinical and translational research, leveraging Crown's extensive data assets and bioinformatics expertise to further solidify its industry position [1] - Post-acquisition, it is anticipated that approximately 23% of Adicon's revenue will come from overseas markets [1]

Market Overview - The market experienced fluctuations on January 26, with significant divergence between large and small indices. The Shenzhen Component Index and the ChiNext Index opened high but fell over 1% during the day. The total trading volume in the Shanghai and Shenzhen markets reached 3.25 trillion yuan, an increase of 163 billion yuan compared to the previous trading day [1] - By the end of the trading session, the Shanghai Composite Index fell by 0.09%, the Shenzhen Component Index decreased by 0.85%, and the ChiNext Index dropped by 0.91% [1] Sector Performance - Major weight stocks represented by the "Three Oil Giants," insurance, and precious metals (stimulated by a surge in international gold prices) performed strongly, effectively offsetting the impact of declines in most individual stocks on the indices [4] - The recent signals from regulatory authorities regarding "counter-cyclical adjustments" aim to guide the market towards stability and suppress excessive speculation, leading to a cooling of pure thematic speculation [4] - The market is characterized as a typical structural adjustment day, with stable indices reflecting the support from weight stocks and the regulatory intent to stabilize the market, while a large number of individual stocks hitting the limit down indicates a shift in funds ahead of the performance window [4] Investment Opportunities - The "AI traffic super entrance" has become a battleground as Baidu and Tencent announced cash red envelope distributions, with Baidu offering a total of 500 million yuan and Tencent 1 billion yuan in cash red envelopes during the Spring Festival period [6] - The ongoing demand for AI ASIC chips is expected to drive significant growth in the semiconductor industry, with companies like Chiplet technology providers gaining traction due to the increasing need for efficient and cost-effective AI chips [24][25] Company Insights - Chip Origin Co., Ltd. is positioned at a critical turning point with a strong order explosion, projected revenue growth of 35.81% year-on-year, and a significant increase in new orders by 103.41% [14][16] - The company’s unique business model of "IP licensing + one-stop chip customization" minimizes product inventory risks and capitalizes on the growing demand for AI chips, with a substantial portion of its revenue coming from AI-related orders [15][24] - The company has established a robust order backlog, with 50.75 billion yuan in hand orders, indicating high visibility for future revenue [22] Regulatory Environment - The Shanghai Futures Exchange has implemented measures to strengthen market risk control in response to the strong performance of silver and other metal markets, including penalties for specific clients and new trading limits [7] - Thailand has adopted a clear policy direction regarding silver trading, prioritizing strong interventions or even suspending trading during extreme price fluctuations to control risks [8] Global Context - The geopolitical situation in Iran remains tense, with the U.S. deploying a multi-layered deterrent and strike system in the region, which could have implications for global markets and energy prices [9][10] - The Nipah virus outbreak in India has raised concerns, with a high mortality rate and no effective vaccine or treatment available, potentially impacting healthcare-related investments [12][13]

Core Viewpoint - The advancement of national policies related to reproductive health will significantly increase the demand for fertility health testing, positively impacting the core business development of the company [2] Group 1: Company Strategy - The company has been deeply engaged in the reproductive health sector for many years, focusing on a three-tier prevention system that includes pre-pregnancy, prenatal, and newborn care [2] - The company plans to leverage advanced testing technologies, a comprehensive product system, and a broad network of hospital collaborations to seize market opportunities [2] Group 2: Market Impact - The expansion of the fertility health testing market is expected to support efforts in preventing birth defects [2]

Core Viewpoint - The report by Jefferies gives a "Buy" rating to Adicon Holdings (09860) with a target price of HKD 12.60, highlighting the company's strategic positioning in AI medical diagnostics and the significant acquisition of Crown Bioscience, which will enhance its capabilities in drug development and diagnostics [1][5]. Group 1: AI Strategy - Adicon's AI strategy is built around three main pillars: 1. An AI-assisted pathology reading system that increases slide reading efficiency by 6-7 times compared to manual methods, with quality control features for error detection [1][5]. 2. The launch of a generative AI laboratory assistant named "Aixiaoyi" for clinicians and a clinical large language model "Wenyi" developed in collaboration with Huawei, integrated into clinical workflows for report quality control, flow cytometry analysis, and patient intelligent diagnosis portals [1][5]. 3. Completion of a 20-year integration, governance, and cleansing of precision medicine testing data, with ongoing exploration of commercialization opportunities in areas like commercial insurance. The company currently performs approximately 10 million AI-assisted image interpretations annually [1][5]. Group 2: Acquisition of Crown Bioscience - Adicon announced the acquisition of Crown Bioscience for up to USD 204 million, which includes an initial payment of USD 120 million and deferred payments based on performance targets [2][6]. - Crown Bioscience specializes in translational oncology and immuno-oncology, possessing the largest commercial PDX model library globally and deep expertise in CDX models and biomarker solutions, serving over 1,100 clients, including the top 20 global pharmaceutical companies [2][6]. - The acquisition is expected to significantly enhance Adicon's capabilities in preclinical and translational research, further solidifying its industry position through Crown's rich data assets and bioinformatics expertise. Post-acquisition, approximately 23% of Adicon's revenue is anticipated to come from international markets [2][6].

Core Viewpoint - The report from Jefferies gives a "Buy" rating for ADICON Holdings (09860) with a target price of HKD 12.60, highlighting the company's strategic positioning in AI medical diagnostics and the significant acquisition of Crown Bioscience, which will enhance its capabilities in drug development and diagnostics [1][2]. Group 1: AI Strategy - ADICON's AI strategy is built around three main pillars: the AI-assisted pathology reading system, which increases reading efficiency by 6-7 times compared to manual methods and includes quality control features for error correction [1]. - The company has launched generative AI tools for clinical doctors, such as "Aixiaoyi" and a clinical large language model developed in collaboration with Huawei, which are integrated into diagnostic workflows for quality control and patient diagnosis [1]. - ADICON has completed a 20-year integration, governance, and cleansing of precision medicine testing data and is exploring commercialization opportunities in areas like commercial insurance, currently performing approximately 10 million AI-assisted image interpretations annually [1]. Group 2: Acquisition of Crown Bioscience - ADICON announced the acquisition of Crown Bioscience for up to USD 204 million, which includes an initial payment of USD 120 million and deferred payments based on performance targets [2]. - Crown Bioscience specializes in translational oncology and immuno-oncology, possessing the largest commercial PDX model library globally and a strong presence in CDX models and biomarker solutions, serving over 1,100 clients, including the top 20 pharmaceutical companies [2]. - The acquisition is expected to significantly enhance ADICON's capabilities in preclinical and translational research, with Crown's data assets and bioinformatics expertise further solidifying its industry position, and it is anticipated that around 23% of ADICON's revenue will come from international markets post-acquisition [2].

Core Viewpoint - The report from Jefferies gives a "Buy" rating for Adicon Holdings (09860) with a target price of HKD 12.60, highlighting the company's strategic positioning in AI medical diagnostics and the significant acquisition of Crown Bioscience as key factors to enhance its capabilities in drug development and diagnostics value chain [1][2]. Group 1: AI Strategy - Adicon's AI strategy is built around three main pillars: the AI-assisted pathology reading system, which increases reading efficiency by 6-7 times compared to manual methods and includes quality control features for error correction [1]. - The company has launched generative AI tools for clinical doctors, such as "Aixiaoyi" and a clinical large language model developed in collaboration with Huawei, which are integrated into diagnostic workflows for quality control and patient diagnosis [1]. - Adicon has completed the integration, governance, and cleaning of 20 years of precision medicine testing data and is exploring commercialization opportunities in areas like commercial insurance, currently performing approximately 10 million AI-assisted image interpretations annually [1]. Group 2: Acquisition of Crown Bioscience - Adicon announced the acquisition of Crown Bioscience for up to USD 204 million, which includes an initial payment of USD 120 million and deferred payments based on performance targets [2]. - Crown Bioscience specializes in translational oncology and immuno-oncology, possessing the largest commercial PDX model library globally and serving over 1,100 clients, including the top 20 pharmaceutical companies [2]. - The acquisition is expected to significantly enhance Adicon's capabilities in preclinical and translational research, with approximately 23% of its revenue projected to come from overseas markets post-transaction [2].

Market Overview - The Hong Kong stock market opened higher on January 12, with the Hang Seng Index rising by 0.55% to 26,376.84 points, the Hang Seng Tech Index increasing by 0.88% to 5,737.43 points, the National Enterprises Index up by 0.75% to 9,116.01 points, and the Red Chip Index gaining 0.68% to 4,129.13 points [1] Company News - Sunny Optical Technology (02382.HK) reported a December smartphone lens shipment of 95.592 million units, a year-on-year decrease of 8.9%. The automotive lens shipment was 7.477 million units, a year-on-year increase of 17.7%. Smartphone camera module shipments were 37.744 million units, down 29.3% year-on-year, primarily due to customer inventory control and holiday factors [2] - Orient Overseas International (00316.HK) reported a 17.2% year-on-year decrease in fourth-quarter shipping revenue to USD 2.081 billion. Total cargo volume increased by 0.8%, and capacity rose by 4.5%. The overall load factor decreased by 3.1% compared to the same period in 2024, with average revenue per standard container down 17.8% year-on-year [2] - China Jinmao (00817.HK) achieved a cumulative contracted sales amount of RMB 113.5 billion for 2025, representing a year-on-year increase of 15.52% [3] - R&F Properties (02777.HK) reported total sales revenue of approximately RMB 14.21 billion for 2025, a year-on-year increase of 26.54% [4] - Zhongliang Holdings (02772.HK) reported a cumulative contracted sales amount of approximately RMB 12.07 billion for 2025, a year-on-year decrease of 32.68% [5] - Greenland Hong Kong (00337.HK) reported contracted sales of approximately RMB 7.214 billion for 2025, a year-on-year decrease of 21.66% [6] - Longyuan Power (00916.HK) completed a cumulative power generation of 76.4694 million MWh for 2025, a year-on-year increase of 1.22% [7] - Dekang Agriculture and Animal Husbandry (02419.HK) reported sales of 1.1097 million pigs in December, generating revenue of RMB 1.664 billion [8] - COFCO Joycome (01610.HK) reported a December pig output of 567,000 heads, a month-on-month increase of 1.43% [9] - Hengding Industrial (01393.HK) reported a coal production of 5.415 million tons for 2025, a year-on-year increase of 31% [10] Industry Insights - Dongwu Securities suggests that the Hong Kong stock market is entering a period of oscillation and upward movement, emphasizing the importance of dividends as a base and the potential for technology growth in the first half of the year [15] - CITIC Construction Investment highlights the strong performance of copper and aluminum in the recent market, indicating that copper prices are expected to continue rising, with a target of USD 13,000 not being the peak for this cycle [15] - Zhongtai Securities notes that China's rare earths have become a crucial strategic component in the global high-tech industry chain amid increasing Sino-US tech competition, recommending focus on resource companies with high concentration and barriers [16]

Core Insights - The company has established a strategic partnership with N Health and Bangkok Dusit Medical Services to introduce advanced microRNA cancer screening solutions in Thailand, marking a significant step forward in early cancer detection and patient outcomes in the region [1][2] Group 1: Strategic Partnership and Market Growth - The partnership aims to penetrate the rapidly growing health check market in Thailand, which is expected to reach approximately $500 million by 2030, with a compound annual growth rate (CAGR) of 9.2% starting from 2025 [1] - The specialized health check segment is the fastest-growing part of the market, indicating strong demand for advanced and targeted screening solutions [1] Group 2: Cancer Screening Solutions - The partnership will leverage the company's cutting-edge miRNA technology and innovative screening solutions, such as GASTROClear for gastric cancer and LUNGClear for lung cancer, to improve cancer treatment standards in the region [2] - Nearly 60 hospitals within the N Health network will adopt the cancer screening tests, supporting broader access to early disease detection services across Thailand and Southeast Asia [2] Group 3: Home Testing Kits Launch - The company announced the launch of new home screening test kits, HELICORapid for H. pylori detection and FITRapid for fecal occult blood detection, in Thailand, following approvals from the Thai FDA [3] - These home test kits are the first of their kind in the Thai market, designed to integrate sample collection and testing into a single, user-friendly device, significantly reducing contamination and user error risks [3][4] Group 4: Accessibility and Consumer Engagement - The home test kits will be distributed through modern trade channels and pharmacies across Thailand, catering to evolving consumer healthcare behaviors and the increasing demand for preventive, self-diagnostic solutions [4] - The launch emphasizes the company's mission to democratize early detection, empowering individuals with practical tools to manage their health and support the healthcare system through early intervention and increased disease awareness [4]